CTLA4 and neoplasm: Immune checkpoint molecules—including PD-1, PD-L1, and CTLA-4—are pivotal to tumor immune evasion mechanisms, and monoclonal antibodies targeting these pathways have revolutionized cancer therapy (31–33).